AZN ▼ -1.3% - AstraZeneca PLC
$AZN - Talk FDA Grants Accelerated Approval to a New Breast Cancer Treatment (SM Circulations)
AstraZeneca fell 1.3% today despite the company receiving FDA accelerated approval for a new breast cancer treatment. The decline suggests investors may have been expecting a stronger market reaction to the regulatory milestone, or broader market headwinds outweighed the positive news.
04-SEP-2026 03:40 PM ET
Share this post
More filings for $AZN
View full $AZN filing history →💬 Comments
Loading comments…
Leave a comment
